|
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
| Revenues: | ||
| License revenue | $ 911us-gaap_LicensesRevenue | $ 911us-gaap_LicensesRevenue |
| Total revenue | 911us-gaap_Revenues | 911us-gaap_Revenues |
| Operating expenses: | ||
| Research and development | 1,431us-gaap_ResearchAndDevelopmentExpense | 949us-gaap_ResearchAndDevelopmentExpense |
| General and administrative | 1,095us-gaap_GeneralAndAdministrativeExpense | 896us-gaap_GeneralAndAdministrativeExpense |
| Total operating expenses | 2,526us-gaap_OperatingExpenses | 1,845us-gaap_OperatingExpenses |
| Loss from operations | (1,615)us-gaap_OperatingIncomeLoss | (934)us-gaap_OperatingIncomeLoss |
| Other expense: | ||
| Other expense, net | (3)us-gaap_OtherNonoperatingIncomeExpense | (6)us-gaap_OtherNonoperatingIncomeExpense |
| Non-cash loss on changes in the fair value of warrants | (3,279)us-gaap_FairValueAdjustmentOfWarrants | (864)us-gaap_FairValueAdjustmentOfWarrants |
| Other expense, net | (3,282)us-gaap_NonoperatingIncomeExpense | (870)us-gaap_NonoperatingIncomeExpense |
| Net loss and comprehensive loss | $ (4,897)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic | $ (1,804)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
| Basic net loss per common share (in dollars per share) | $ (0.04)us-gaap_EarningsPerShareBasic | $ (0.02)us-gaap_EarningsPerShareBasic |
| Diluted net loss per common share (in dollars per share) | $ (0.04)us-gaap_EarningsPerShareDiluted | $ (0.02)us-gaap_EarningsPerShareDiluted |
| Weighted average shares used in computing basic net loss per common share (in shares) | 110,170us-gaap_WeightedAverageNumberOfSharesOutstandingBasic | 88,929us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
| Weighted average shares used in computing diluted net loss per common share (in shares) | 110,305us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding | 88,929us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|